Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
Senbo Liu(First Affiliated Hospital of Zhengzhou University), Zhenqiang Sun(First Affiliated Hospital of Zhengzhou University), Shengyun Hu(First Affiliated Hospital of Zhengzhou University), Baojing Tuo(First Affiliated Hospital of Zhengzhou University), Wenkang Wang(ZheJiang Institute For Food and Drug Control), Haifeng Sun(First Affiliated Hospital of Zhengzhou University), Qiming Wang(Hunan Cancer Hospital), Bin Jia(First Affiliated Hospital of Zhengzhou University), Yang Liu(Zhengzhou University)
Cited by 130
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
|Cell Death Discovery|2024|145
Intensive Care Unit-Acquired Weakness: A Review of Recent Progress With a Look Toward the Future
|Frontiers in Medicine|2020|117
Roles of exosomes in immunotherapy for solid cancers
|Cell Death and Disease|2024|106